News articles about Urogen Pharma (NASDAQ:URGN) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Urogen Pharma earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 47.6584516073698 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
A number of research firms have recently weighed in on URGN. Cowen and Company began coverage on Urogen Pharma in a research note on Tuesday, May 30th. They issued an “outperform” rating on the stock. Zacks Investment Research raised Urogen Pharma from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research note on Wednesday, August 2nd. Oppenheimer Holdings, Inc. set a $32.00 price target on Urogen Pharma and gave the company a “buy” rating in a research note on Monday, August 14th. Jefferies Group LLC began coverage on Urogen Pharma in a research note on Tuesday, May 30th. They issued a “buy” rating and a $27.00 price target on the stock. Finally, Raymond James Financial, Inc. began coverage on Urogen Pharma in a research note on Tuesday, May 30th. They issued an “outperform” rating and a $25.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Urogen Pharma has an average rating of “Buy” and a consensus target price of $26.00.
Urogen Pharma (NASDAQ:URGN) opened at 28.53 on Wednesday. Urogen Pharma has a 1-year low of $13.01 and a 1-year high of $29.89. The firm’s market cap is $371.15 million. The stock has a 50 day moving average price of $19.92 and a 200-day moving average price of $18.36.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Urogen Pharma (URGN) Share Price” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/2887644/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-urogen-pharma-urgn-share-price.html.
Urogen Pharma Company Profile
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.